newsfilter
← Latest News
Business Wire·

Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the Parent Project Muscular Dystrophy (PPMD) Virtual Annual Conference, which begins Wednesday, July 22, 2020.